Relationship analysis between hepoatocelluar carcinoma incidence and hepatitis B e antigen expression in chronic hepatitis B patients with long-term treatment of nucleoside analogues therapy
10.3760/cma.j.issn.1673-4904.2013.34.007
- VernacularTitle:核苷类似物长期治疗的慢性乙型肝炎患者肝癌发生与乙型肝炎e抗原表达的关系分析
- Author:
Yong CHEN
;
Wenjing SUN
;
Xiaoyong HAN
- Publication Type:Journal Article
- Keywords:
Hepatitis B,chronic;
Nucleosides;
Carcinoma,hepatocellular;
Hepatitis
- From:
Chinese Journal of Postgraduates of Medicine
2013;36(34):20-22
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze and evaluate the relationship between hepoatocelluar carcinoma incidence and hepatitis B e antigen (HBeAg) expression in choronic hepatitis B (CHB) patients with long-term treatment of nucleoside analogue therapy.Methods The clinical data of 56 CHB patients with long-term treatment of nucleoside analogue therapy except for hepoatocelluar carcinoma (experimental group)were summarized retrospectively,and all patients underwent anti-viral therapy with no less than 5 years.The clinical data of 56 CHB patients without anti-viral therapy in the same period (control group) were collected.The risk factors of hepoatocelluar carcinoma were analyzed.Results The incidence of hepoatocelluar caroinoma was 7.14％ (4/56) in experimental group and 19.64％ (11/56) in control group,and there was significant difference (P ＜ 0.05).The incidence of hepoatocelluar carcinoma was 0 in patients with positive HBeAg without cirrhosis (36 cases) in experimental group and 1/8 in patients with negative HBeAg without cirrhosis in experimental group,and there was significant difference (P＜ 0.05).Conclusions Long-term treatment of nucleoside analogue therapy can reduce but bot eliminate the hepatocellular carcinoma risk in patients with CHB,especially in those with negative HBeAg.HBeAg negativity is a significant risk factor for the development of hepallerular carcinoma in CHB patients without liver cirrhosis.
